Shares of UCB SA (OTCMKTS:UCBJY – Get Free Report) reached a new 52-week high during trading on Monday . The stock traded as high as $101.51 and last traded at $101.16, with a volume of 432584 shares traded. The stock had previously closed at $95.06.
UCB Price Performance
The company has a fifty day simple moving average of $97.37 and a two-hundred day simple moving average of $94.68. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Recommended Stories
- Five stocks we like better than UCB
- What is the Nasdaq? Complete Overview with History
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- Conference Calls and Individual Investors
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
